Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ProQR Therapeutics N.V. (PRQR : NSDQ)
 
 • Company Description   
ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands.

Number of Employees: 150

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.67 Daily Weekly Monthly
20 Day Moving Average: 1,193,901 shares
Shares Outstanding: 71.29 (millions)
Market Capitalization: $48.06 (millions)
Beta: 0.97
52 Week High: $9.09
52 Week Low: $0.53
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.87% 0.38%
12 Week -34.55% -28.06%
Year To Date -91.58% -90.20%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ZERNIKEDREEF 9
-
LEIDEN,P7 2333 CK
NLD
ph: 31-88-166-7000
fax: -
ir@proqr.com http://www.proqr.com
 
 • General Corporate Information   
Officers
Daniel de Boer - Chief Executive Officer
Theresa Heggie - Chief Operating Officer
Smital Shah - Chief Business and Financial Officer
Aniz Girach - Chief Medical Officer
Naveed Shams - Chief Scientific Officer

Peer Information
ProQR Therapeutics N.V. (CORR.)
ProQR Therapeutics N.V. (RSPI)
ProQR Therapeutics N.V. (CGXP)
ProQR Therapeutics N.V. (BGEN)
ProQR Therapeutics N.V. (GTBP)
ProQR Therapeutics N.V. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N71542109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 71.29
Most Recent Split Date: (:1)
Beta: 0.97
Market Capitalization: $48.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.86 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.43
Price/Cash Flow: -
Price / Sales: 16.13
EPS Growth
vs. Year Ago Period: 26.67%
vs. Previous Quarter: 26.67%
Sales Growth
vs. Year Ago Period: 714.71%
vs. Previous Quarter: 407.33%
ROE
03/31/22 - -54.60
12/31/21 - -59.74
09/30/21 - -65.00
ROA
03/31/22 - -33.17
12/31/21 - -37.01
09/30/21 - -41.70
Current Ratio
03/31/22 - 7.27
12/31/21 - 6.94
09/30/21 - 5.10
Quick Ratio
03/31/22 - -
12/31/21 - 6.94
09/30/21 - 5.10
Operating Margin
03/31/22 - -2,469.79
12/31/21 - -4,113.78
09/30/21 - -3,747.12
Net Margin
03/31/22 - -2,469.79
12/31/21 - -4,113.78
09/30/21 - -3,747.12
Pre-Tax Margin
03/31/22 - -2,478.65
12/31/21 - -4,546.50
09/30/21 - -3,730.07
Book Value
03/31/22 - 1.58
12/31/21 - 1.88
09/30/21 - 3.01
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.38
12/31/21 - 0.35
09/30/21 - 0.14
Debt-to-Capital
03/31/22 - 27.69
12/31/21 - 25.77
09/30/21 - 12.03
 

Powered by Zacks Investment Research ©